Glaxo Wellcome/SmithKline Beecham merger completed at last
The long wait that Glaxo Wellcome and SmithKline Beecham have had toendure in completing their merger is now over, after the deal was finally cleared by the US Federal Trade Commission and the UK High Court. Trading in GlaxoSmithKline shares in London and New York started on December 27 (see also page 11).
Jean-Pierre Garnier, GSK's chief executive, said that the new entity "is well placed to respond to the health care challenges of the twenty-first century," noting its position as market leader "in four of the five largest therapeutic categories in the pharmaceutical industry."
Market leader in four out of five areas
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze